| Literature DB >> 26717798 |
Annalina Avram1, Cátia Duarte2, Maria José Santos3, Charalampos Papagoras4, Konstantinos Ritis5, Roberto Scarpioni6, Wolfgang A Schmidt7, Panagiotis Skendros8.
Abstract
A subgroup of patients with gouty arthritis have a chronic recurring form that is particularly difficult to treat. Such patients experience repeated flares and often have abundant tophi. Many also have underlying comorbidities, such as renal impairment, cardiovascular disease, gastrointestinal disorders, obesity, and hypertension, which contraindicate the use of standard anti-inflammatory medications. Five patients with difficult to treat gouty arthritis who were either candidates and/or treated with anti-IL therapy are described.Entities:
Keywords: Anakinra; Anti-IL-1β therapy; Canakinumab; Gouty arthritis; Tophaceous gout
Mesh:
Substances:
Year: 2015 PMID: 26717798 DOI: 10.1016/S1297-319X(15)30004-X
Source DB: PubMed Journal: Joint Bone Spine ISSN: 1297-319X Impact factor: 4.929